熱門資訊> 正文
Can-Fite BioPharma推出尽力而为的ADS和担保书
2025-07-24 05:41
- Can-Fite BioPharma (NYSE:CANF) is offering up to 4.9 million ADSs (representing 1.47 billion ordinary shares) and 4.9 million common warrants in a best-efforts offering.
- Each ADS will be sold with one common warrant at an assumed combined price of $1.02/unit.
- Pre-funded warrants are also offered as an alternative for buyers who would exceed 4.99% (or 9.99%) ownership thresholds post-offering.
- Each pre-funded warrant, priced at $1.019, is exercisable immediately and comes with one common warrant.
- The offering also includes up to 343,138 placement agent qarrants, representing 102.9 million ordinary shares.
- In total, up to 10.1 million ADSs (3.04 billion ordinary shares) may be issued upon full exercise of all warrants.
- All Common Warrants will have a 5-year term and become exercisable upon issuance.
- Source: SEC filing
More on Can-Fite Biopharma
- Seeking Alpha’s Quant Rating on Can-Fite Biopharma
- Historical earnings data for Can-Fite Biopharma
- Financial information for Can-Fite Biopharma
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
